Market capitalization | $116.24m |
Enterprise Value | $-48.67m |
P/E (TTM) P/E ratio | negative |
P/B ratio (TTM) P/B ratio | 0.70 |
Revenue (TTM) Revenue | $0.00 |
EBIT (operating result TTM) EBIT | $-63.38m |
Cash position | $181.70m |
EPS (TTM) EPS | $-2.13 |
P/E forward | negative |
As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.
8 Analysts have issued a Alto Neuroscience forecast:
8 Analysts have issued a Alto Neuroscience forecast:
Sep '24 |
+/-
%
|
||
Revenue | - - |
-
|
|
Gross Profit | -0.49 -0.49 |
-
|
|
EBITDA | -63 -63 |
-
|
EBIT (Operating Income) EBIT | -63 -63 |
-
|
Net Profit | -57 -57 |
-
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Alto Neuroscience, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of psychiatric drugs. Its pipeline is composed of five clinical-stage assets which initially target depressive disorder and schizophrenia population. The company was founded by Amit Etkin, Dan Segal, and Wei Wu on March 25, 2019 and is headquartered in Los Altos, CA.
Head office | United States |
CEO | Amit Etkin |
Employees | 63 |
Founded | 2019 |
Website | www.altoneuroscience.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.